Hyperpolarized 13C Pyruvate

Phase 2Small molecule

UUniversity of Maryland, Baltimore

Hyperpolarized 13C Pyruvate is one of 271 small molecule programs targeting Glioma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

270

Competitors

Pipeline

Status by Indication[3][1]

Indication

GliomaActive, not recruiting

MetastasisActive, not recruiting

Brain InjuryActive, not recruiting

Pancreatic CancerActive, not recruiting

Prostate CancerActive, not recruiting

GlioblastomaActive, not recruiting

Cervical CancerActive, not recruiting

Pulmonary Arterial HypertensionActive, not recruiting

GliomaPhase 1

Active, not recruiting

MetastasisPhase 1

Active, not recruiting

Brain InjuryPhase 1

Active, not recruiting

Pancreatic CancerPreclinical

Active, not recruiting

Prostate CancerPhase 1

Active, not recruiting

GlioblastomaPhase 1

Active, not recruiting

Cervical CancerPhase 2

Active, not recruiting

Pulmonary Arterial HypertensionPreclinical

Active, not recruiting

Competition

Competitive Landscape

1399 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Hyperpolarized 13C Pyruvate

UUniversity of Maryland, Baltimore

Phase 2

1 2

Novantrone

Pfizer

Preclinical

5 3

Mekinist

Novartis

Preclinical

3 4

Trexall

Alnylam Pharmaceuticals

Preclinical

—5

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Preclinical

2 6

Viagra

VViatris Specialty LLC

Preclinical

1 7

Ranexa

MMenarini International Operations Luxembourg SA

Preclinical

1 8

Prednisone/prednisolone

Roche

Preclinical

3 9

Triptorelin Pamoate

Ipsen

Preclinical

2 10

Osmitrol

BB. Braun Medical Inc.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Not yet recruiting

Immunotherapy

NCT05805358

Q4 2026

Phase 1Recruiting

Prostate Cancer

NCT02526368

Recruiting

Brain Tumors

NCT03067467

Q1 2027

Phase 1Recruiting

Metastasis

NCT03324360

Q4 2027

Phase 1Recruiting

Brain Injury

NCT06103201

Phase 2Recruiting

Magnetic Resonance Imaging

NCT04698564

Clinical

Trials by Indication[1]

Cervical Cancer2 trials

Hyperpolarized 13C Pyruvate MRI for Early Immune Evaluation in Cervical Cancer Patients At Baseline and CCRT Therapy

Completed·—·Phase 2·NCT04951921·6 enrolled

Hyperpolarized 13C MR Imaging of Lactate in Patients With Locally Advanced Cervical Cancer (LACC) Cervical Cancer

Terminated·SSunnybrook Health Sciences Centre·Phase 1·NCT03129776·4 enrolled

Magnetic Resonance Imaging2 trials

A Study of [13C]Pyruvate as an Imaging Agent for Magnetic Resonance Imaging in Healthy Volunteers

Enrolling by invitation·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT05041166·50 enrolled

Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging

Recruiting·UUniversity of Maryland, Baltimore·Phase 2·NCT04698564·20 enrolled

Glioblastoma1 trial

Hyperpolarized Carbon-13 (13C) Pyruvate Imaging in Patients With Glioblastoma

Active, not recruiting·SSusan Chang·Phase 1·NCT04019002·17 enrolled

Brain Injury1 trial

Hyperpolarized 13C-pyruvate Metabolic MRI With Traumatic Brain Injury

Recruiting·UUniversity of Maryland, Baltimore·Phase 1·NCT06103201·15 enrolled

Immunotherapy1 trial

Hyperpolarized 13C MRI for Cancer Immunotherapy

Not yet recruiting·—·Phase 2·NCT05805358·90 enrolled

10 more indications

Imaging1 trial

Hyperpolarized MR Imaging with Carbon-13 Pyruvate in the Human Body

Recruiting·NNational Heart Centre Singapore·Phase 2·NCT06645691·200 enrolled

Metastasis1 trial

Role of Hyperpolarized 13C-Pyruvate MR Spectroscopy in Patients With Intracranial Metastasis Treated With (SRS)

Recruiting·SSunnybrook Health Sciences Centre·Phase 1·NCT03324360·276 enrolled

Advanced Solid Tumors1 trial

Hyperpolarized 13C MRI as a Biomarker in Advanced Solid Tumors

Recruiting·RRobert Bok, MD, PhD·Phase 1/2·NCT05599048·65 enrolled

Neuroendocrine Tumors1 trial

Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors

Recruiting·UUniversity of California, San Francisco·Phase 2·NCT05746208·29 enrolled

Pancreatic Cancer1 trial

Hyperpolarized 13C MRI to Predict Response in Pancreatic Cancer

Recruiting·UUniversity of California, San Francisco··NCT06600906·70 enrolled

Prostate Cancer1 trial

Pilot Study of (MR) Imaging with Pyruvate (13C) to Detect High Grade Prostate Cancer

Recruiting·IIvan de Kouchkovsky, MD·Phase 1·NCT02526368·80 enrolled

Cancers1 trial

HP Pyruvate MRI in Cancers

Recruiting·UUniversity of Maryland, Baltimore·Phase 1/2·NCT05697406·25 enrolled

Recruiting·UUniversity of Maryland, Baltimore·Phase 1·NCT04772456·5 enrolled

Sources

References

[1]
ClinicalTrials.gov — 17 trial records for Hyperpolarized 13C Pyruvate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Hyperpolarized 13C Pyruvate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Hyperpolarized 13C Pyruvate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Maryland, Baltimore company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: UUniversity of Maryland, Baltimore

Hyperpolarized 13C Pyruvate

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2026

Q1 2027

Q4 2027

Trials by Indication[1]

Cervical Cancer2 trials

Magnetic Resonance Imaging2 trials

Glioblastoma1 trial

Brain Injury1 trial

Immunotherapy1 trial

Imaging1 trial

Metastasis1 trial

Advanced Solid Tumors1 trial

Neuroendocrine Tumors1 trial

Pancreatic Cancer1 trial

Prostate Cancer1 trial

Cancers1 trial

Pulmonary Arterial Hypertension1 trial

Brain Tumors1 trial

Glioma1 trial

References

Drug Info

Quick Facts

Related News